The FDA will require new warnings on Ozempic, Wegovy, Zepbound and Mounjaro after data suggested a possible rise in a rare optic‑nerve condition.
The FDA will require new warnings on Ozempic, Wegovy, Zepbound and Mounjaro after data suggested a possible rise in a rare optic‑nerve condition.